Journal
STEROIDS
Volume 102, Issue -, Pages 27-31Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.steroids.2015.06.015
Keywords
Glucocorticoids; Nongenomic mechanism; Drug development; Side effects; Anti-inflammation; Clinical usage
Funding
- National Natural Science Foundation of China [31371200]
- Military Medical Research Project [BWS11J016, BWS14J021]
- National Instrumentation Program [2013YQ190467]
Ask authors/readers for more resources
Glucocorticoids (GCs) are widely used in clinical practice as potent anti-inflammatory and immunosuppressive agents. Unfortunately, they can also produce numerous and potentially serious side effects that limit their usage. This problem represents the driving force for the intensive search for novel GCs with a better benefit-risk ratio compared to conventional GCs. GCs are believed to take effects mainly through classical genomic mechanisms, which are also largely responsible for GCs' side effects. However, in addition to these genomic effects, GCs also demonstrate rapid genomic-independent activities. It has become increasingly evident that some of the anti-inflammatory, immunosuppressive, anti-allergic and anti-shock effects of GCs could be mediated through nongenomic mechanisms. Thus, theoretically, trying to use nongenomic mechanisms of GCs more intensively may represent a novel strategy for development of GCs with low side effect profile. The new GCs' drugs will take clinical effects mainly via nongenomic mechanisms and do not execute the classical genomic mechanism to reduce side effects. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available